GlassScriptPhysician profile
Edward K Barnes
NPI 1770538738
$3,103.42
in general payments reported to CMS, 2019-2025
44 companies · $873 in 2025
The $873 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2021: $11.92 · 2023: $996 · 2024: $1,029 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,862 · Education: $36.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,862.05 |
| Education | $36.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $395.55 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $177.93 | 2023-2025 | Talvey, Darzalex, Erleada |
| Daiichi Sankyo INC. | $170.27 | 2023-2025 | Enhertu |
| Abbvie INC. | $167.19 | 2023-2025 | Venclexta |
| Gilead Sciences, INC. | $165.30 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $161.24 | 2023-2025 | Calquence, Tagrisso, Imfinzi |
| Apellis Pharmaceuticals, INC. | $136.16 | 2023 | Empaveli |
| Novartis Pharmaceuticals Corporation | $130.16 | 2023-2025 | |
| Pfizer INC. | $106.19 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $87.19 | 2023-2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $84.79 | 2023-2025 | Zepzelca |
| Aveo Pharmaceuticals, INC. | $81.87 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $74.67 | 2019-2025 | Opdivo, Krazati |
| Incyte Corporation | $73.51 | 2023-2024 | Pemazyre, Monjuvi, Jakafi |
| Celgene Corporation | $70.50 | 2023-2024 | Reblozyl |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $68.80 | 2023-2024 | Ojjaara, Zejula, Jemperli |
| Eisai INC. | $66.84 | 2023-2025 | |
| Array Biopharma INC | $62.89 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Genzyme Corporation | $60.83 | 2023-2024 | |
| Beigene USA, INC. | $60.03 | 2023-2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $55.42 | 2023-2024 | |
| Pharmaessentia USA Corporation | $46.05 | 2024-2025 | Besremi |
| Genentech USA, INC. | $44.79 | 2024-2025 | Polivy, Lunsumio, Itovebi |
| Exelixis INC. | $42.32 | 2024 | Cabometyx |
| Astellas Pharma US INC | $42.07 | 2023-2025 | Vyloy, Xospata |
| Tersera Therapeutics LLC | $39.31 | 2023-2025 | Xermelo, Zoladex |
| Biocompatibles, INC. | $38.89 | 2019 | |
| Taiho Oncology, INC. | $37.70 | 2025 | Inqovi, Lonsurf |
| Deciphera Pharmaceuticals INC. | $35.95 | 2024 | Qinlock |
| Ipsen Biopharmaceuticals, INC | $34.45 | 2024 | Onivyde |
| Morphosys, US INC. | $32.49 | 2023 | Monjuvi |
| Seagen INC. | $26.32 | 2023 | Tukysa |
| Sobi, INC | $23.09 | 2025 | |
| Stemline Therapeutics INC. | $22.67 | 2024 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $22.51 | 2025 | Ninlaro |
| Mirati Therapeutics, INC. | $18.93 | 2023 | Krazati |
| Lilly USA, LLC | $18.71 | 2025 | Jaypirca, Verzenio |
| Karyopharm Therapeutics INC. | $17.90 | 2025 | Xpovio |
| Progenics Pharmaceuticals, INC. | $17.73 | 2023 | Pylarify |
| Sumitomo Pharma America, INC. | $17.65 | 2025 | Orgovyx |
| Pharmacosmos Therapeutics INC. | $17.19 | 2024 | Cosela |
| Amgen INC. | $17.04 | 2023 | Lumakras |
| Agios Pharmaceuticals, INC. | $16.53 | 2023 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $15.80 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.